Chronic Pelvic Pain, Chronic Prostatitis
Conditions
Keywords
transcutaneous electric nerve stimulation, andrology
Brief summary
To carry out real world research on the application of electrophysiology and other suitable technologies in the prevention and treatment of male diseases in medical institutions at all levels in Northwest China, and establish a database for the prevention and treatment of male diseases in Northwest China, so as to provide a basis for the formulation of guidelines or consensus on the application of electrophysiology for the prevention and treatment of male diseases in China.
Interventions
DRUGPercutaneous electrical nerve stimulation treatment
Using the percutaneous electrical nerve stimulation instrument to different points of the body
Sponsors
Xijing Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patient meets the diagnostic criteria of National Institutes of Health (NIH)Ⅲ type prostatitis; * NIH-CPSI score \> 10; * The symptoms lasted for more than 3 months and failed to respond to drug treatment for more than 1 month; * Age ≥18 years old and ≤60 years old agrees and signs the informed consent; * Those who did not receive other similar treatment regimens during treatment.
Exclusion criteria
* All kinds of bacterial infection caused by acute or chronic orchitis or epididymitis, acute or chronic prostatitis, lower urinary tract infection; * Benign prostatic hyperplasia, prostate cancer, neurogenic bladder, urethral malformation or stricture and severe neurosis; * For patients with local pain as the main manifestation, attention should be paid to the exclusion of other lesions in the lower abdomen, perineum, lsosacral sites, such as ureteral calculi, bladder calculi, inguinal hernia, pubis, varicocele, epididymitis, rectocolic diseases, lsodorsal myofascitis, etc.; * Complicated with heart, brain, liver and hematopoietic system and other serious primary diseases, local skin infection or skin lesions in the treatment site; * People who have metal implants in their bodies cannot cooperate, such as patients with mental illness. * People who are allergic to the treatment of electrical stimulation or allergic to a variety of drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI) | through study completion, an average of 1 year | Improvement rate = \[(score before treatment - score at the end of treatment)/score before treatment\] ×100% The improvement rate ≥75% was considered to be significant.The improvement rate \< 75% and ≥50% were considered to be better. The improvement rate \< 50% and ≥25% were considered as average efficacy.The improvement rate \< 25% indicates poor efficacy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| international prostate symptom score (IPSS) | through study completion, an average of 1 year | The score improved significantly from baseline |
Countries
China
Contacts
Primary ContactYuan Jianlin, doctor
Backup ContactLu Jun, master
Outcome results
None listed